文献詳細
今月の臨床 婦人科がん診療を支えるトータルマネジメント─各領域のエキスパートに聞く
副作用対策
文献概要
●骨髄毒性は貧血,血小板減少,白血球減少を指すが,特にマネジメントが必要なのは白血球(好中球)減少である.
●発熱性好中球減少症(FN)とG-CSFに関しては各国,各学会からガイドラインが発行されており,それらをもとに本邦でもガイドラインが作成されている.
●2014年9月よりペグフィルグラスチムが本邦でも承認され,FNのリスク回避に寄与する可能性が示唆されている.従来のG-CSFとの使用方法の違いに注意する.
●発熱性好中球減少症(FN)とG-CSFに関しては各国,各学会からガイドラインが発行されており,それらをもとに本邦でもガイドラインが作成されている.
●2014年9月よりペグフィルグラスチムが本邦でも承認され,FNのリスク回避に寄与する可能性が示唆されている.従来のG-CSFとの使用方法の違いに注意する.
参考文献
1) Sugiyama T, et al : Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58 : 31─37, 2000
2) Gordon AN, et al : Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 : 3312─3322, 2001
3) Thigpen JT, et al : Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a gynecologic oncology group study. J Clin Oncol 22 : 3902─3908, 2004
4) Pfisterer J, et al : Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer : an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 : 4699─4707, 2006
5) Ferrandina G, et al : Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26 : 890─896, 2008
6) Katsumata N, et al : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial. Lancet 374 : 1331─1338, 2009
7) Pujade-Lauraine E, et al : Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28 : 3323─3329, 2010
8) Aoki D, et al : A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol 41 : 320─327, 2011
9) Nomura H, et al : Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma : a Japanese Gynecologic Oncology Group study(JGOG2041). Ann Oncol 22 : 636─642, 2011
10) Kitagawa R, et al : Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer : the open-label randomized phase III trial JCOG 0505. J Clin Oncol 33 : 2129─2135, 2015
11) 「輸血療法の実施に関する指針」及び「血液製剤の使用指針」(改訂版).http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/5tekisei3.html
12) Schiffer CA, et al : Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 : 1519─1538, 2001
13) Guminski AD, et al : Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line : a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48 : 229─234, 2001
14) Freifeld AG, et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 : e56─93, 2011
15) de Naurois J, et al : Management of febrile neutropenia : ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5) : v252─256, 2010
16) 日本臨床腫瘍学会 編 : 発熱性好中球減少症(FN)の診療ガイドライン.南江堂,2012
17) Klastersky J, et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038─3051, 2000
18) Carmona-Bayonas A, et al : Prediction of serious complications in patients with seemingly stable febrile neutropenia : validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 33 : 465─471, 2015
19) Smith TJ, et al : 2006 update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187─3205, 2006
20) National Comprehensive Cancer Network(NCCN) guidelines.http://www.nccn.org/index.asp
21) Aapro MS, et al : 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47 : 8─32, 2011
22) 日本癌治療学会 編 : G─CSF適正使用ガイドライン2013年版.第1版,金原出版,2013
23) Hilpert F, et al : Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged>or=70 years with advanced ovarian cancer : a study by the AGO OVAR Germany. Ann Oncol 18 : 282─287, 2007
24) Haim N, et al : The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor(G-CSF) following a prior cycle with febrile neutropenia. Med Oncol 22 : 229─232, 2005
25) Gupta S, et al : Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends 4 : 273─278, 2010
26) Timmer-Bonte JN, et al : Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer : a Dutch Randomized Phase III Study. J Clin Oncol 23 : 7974─7984, 2005
掲載誌情報